Skip to main content
. 2020 May 26;8(1):e000294. doi: 10.1136/jitc-2019-000294

Figure 6.

Figure 6

Dual blockade of PD-1 and TIM-3 synergizes with vvDD in treating refractory lung cancer. (A) Urethane model showing no significant efficacy of PD-1 and TIM-3 dual blockade alone but a synergy with vvDD in treating refractory lung cancer. scale bar, 1 mm. (B, C) Tumor growth (B) and mouse survival analysis (C) showing no significant efficacy of PD-1 and TIM-3 dual blockade alone but a synergy with vvDD in syngeneic LAP0297 lung cancer model. Note, mice died before day 16 in the control (Ctrl) group were not included for the tumor volume calculation at the day 16 timepoint. (D) FACS assays of IFNγ showing increase in the percentage of activated pulmonary CD4+ and CD8+ T cells by combination therapy in urethane model. (E) FACS assays showing increase in the number of activated pulmonary CD4+ and CD8+ T cells by combination therapy in urethane model. (F) IHC showing increased tumor cell apoptosis by combination therapy in urethane model (n=9). Scale bar, 10 µm. FACS, fluorescent activated cell sorting; IFNγ, interferonγ; IHC, immunohistochemistry; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; ns, not significant; PD-1, programmed cell death 1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; vvDD, vaccinia virus with double deletion.